Conclusions : CETP inhibitors are not associated with an increased risk of MACE or all-cause mortality .
There is a trend towards small reductions in nonfatal MI and cardiovascular death , though the clinical importance of such reductions is likely modest
Background : Cholesteryl ester transfer protein ( CETP ) inhibitors increase serum high-density lipoprotein cholesterol ( HDL-c ) concentration ; however , their impact on cardiovascular outcomes is not clear .
This systematic review examines the effect of CETP inhibitors on serum lipid profiles , cardiovascular events , and all-cause mortality .
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
This phase 3 , multiregional , r and omized , double-blind , placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were not at their low-density lipoprotein ( LDL-C ) goal ( as per the National Cholesterol Education Program Adult Treatment Panel III guidelines ) and in those with low high-density lipoprotein cholesterol ( HDL-C ) . Patients on a stable dose of statin ± other lipid-modifying therapies and with LDL-C ≥70 to < 115 , ≥100 to < 145 , ≥130 , or ≥160 mg/dl for very high , high , moderate , or low CHD risk or at LDL-C goal ( per CHD risk category ) with HDL-C ≤40 mg/dl were r and omized in a ratio of 1:1 to anacetrapib 100 mg ( n = 290 ) or placebo ( n = 293 ) for 24 weeks , followed by a 12-week off-drug phase . The co- primary end points were % change from baseline in LDL-C and HDL-C and the safety profile of anacetrapib  . Treatment with anacetrapib  reduced LDL-C ( BQ ) by 37 % ( 95 % confidence interval -42.5 , -31.0 ) and increased HDL-C by 118 % ( 95 % confidence interval 110.6 , 125.7 ) relative to placebo ( p < 0.001 for both ) . Anacetrapib also reduced non-HDL-C , apolipoprotein B , and lipoprotein a and increased apolipoprotein AI versus placebo ( p < 0.001 for all ) . There were no clinical ly meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes , creatine kinase , blood pressure , electrolytes , or adjudicated cardiovascular events . Treatment with anacetrapib substantially reduced LDL-C and also increased HDL-C and was well tolerated over 24 weeks in statin-treated patients with hypercholesterolemia or low
Conclusions : CETP inhibitors are not associated with an increased risk of MACE or all-cause mortality .
There is a trend towards small reductions in nonfatal MI and cardiovascular death , though the clinical importance of such reductions is likely modest
Background : Cholesteryl ester transfer protein ( CETP ) inhibitors increase serum high-density lipoprotein cholesterol ( HDL-c ) concentration ; however , their impact on cardiovascular outcomes is not clear .
This systematic review examines the effect of CETP inhibitors on serum lipid profiles , cardiovascular events , and all-cause mortality .